Year: 2021
Type: review
Abstract: Following the clinical success of cancer immunotherapies such as immune checkpoint inhibitors blocking B7/CTLA-4 or PD-1/PD-L1 signaling and ongoing numerous combination therapies in the clinic,3 bispecific antibodies (BsAbs) are now emerging as a growing class of immunotherapies with the potential to improve clinical efficacy and safety further. Here, we describe four classes of BsAbs: (a) immune effector cell redirectors; (b) tumor-targeted immunomodulators; (c) dual immunomodulators; and (d) dual tumor-targeting BsAbs. This review describes each of these classes of BsAbs and presents examples of BsAbs in development. We reviewed the biological rationales and characteristics of BsAbs and summarized the current status and limitations of clinical development of BsAbs and strategies to overcome limitations. The field of BsAb-based cancer immunotherapy is growing, and more data from clinical trials are accumulating. Thus, BsAbs could be the next generation of new treatment options for cancer patients.
Source: Vaccines
Authors: Gihoon You(Conceptualization, Visualization, Writing – original draft, Writing – review & editing), Jonghwa Won(Conceptualization, Writing – original draft, Writing – review & editing), Yangsoon Lee(Writing – review & editing), Dain Moon(Visualization), Yunji Park(Writing – review & editing), Sang Hoon Lee(Conceptualization, Writing – review & editing), Seung-Woo Lee(Conceptualization, Supervision, Writing – review & editing)
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,160
Awards: G6038835665, G7620953523
OpenAlex ID: W3176971136
